Blood pressure–lowering therapy reduces left ventricular mass, but the question of whether
differences exist among drug classes has not been fully resolved. Our aim was to compare …

Summary Abstract Telmisartan (Micardis®, Pritor®), a highly selective angiotensin II (AII)
type 1 (AT 1) receptor antagonist, is approved for the treatment of hypertension, either as …

Aims Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and
heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to …

Importance of the field: Telmisartan belongs to the angiotensin II type 1 (AT1) receptor
antagonizing class of antihypertensives, which are widely recognized and increasingly …

Blockade of the renin–angiotensin system is an important approach in managing high blood
pressure, and has increasingly been shown to affect cardiovascular disease processes …

Excessive proliferation, inflammation, oxidative stress, and migration induced by angiotensin
II (Ang II), occurring in vascular smooth muscle cells (VSMCs) during vascular remodelling …

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
(ONTARGET™) showed that the angiotensin II receptor blocker (ARB) telmisartan was as …

We studied the effect of an eight-week treatment with telmisartan (5 mg kg− 1 day− 1) on
cardiovascular complications that are associated with type 2 diabetes in a neonatal rat …

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
(ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not …

Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative
stress in animal studies. We investigated candesartan's effect on the production of NO and …